doorgaan naar inhoud
Price indexes for clinical trial research : a feasibility study Voorbeeldweergave van dit item
SluitenVoorbeeldweergave van dit item
Bezig met controle...

Price indexes for clinical trial research : a feasibility study

Auteur: Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Uitgever: Cambridge, Mass. : National Bureau of Economic Research, 2013.
Serie: Working paper series (National Bureau of Economic Research), no. 18918.
Editie/Formaat:   eBoek : Document : EngelsAlle edities en materiaalsoorten bekijken.
Database:WorldCat
Samenvatting:
We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose  Meer lezen...
Beoordeling:

(nog niet beoordeeld) 0 met beoordelingen - U bent de eerste

Onderwerpen
Meer in deze trant

 

Zoeken naar een online exemplaar

Zoeken naar een in de bibliotheek beschikbaar exemplaar

&AllPage.SpinnerRetrieving; Bibliotheken met dit item worden gezocht…

Details

Genre: Document, Internetbron
Soort document: Internetbron, Computerbestand
Alle auteurs / medewerkers: Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
OCLC-nummer: 835500084
Opmerkingen: Title from http://www.nber.org/papers/18918 viewed April 4, 2013.
"March 2013."
Beschrijving: 1 online resource (35 p.) : ill.
Serietitel: Working paper series (National Bureau of Economic Research), no. 18918.
Verantwoordelijkheid: Ernst R. Berndt, Iain M. Cockburn.

Fragment:

We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services.

Beoordelingen

Beoordelingen door gebruikers
Beoordelingen van GoodReads worden opgehaald...
Bezig met opvragen DOGObooks-reviews...

Tags

U bent de eerste.
Bevestig deze aanvraag

Misschien heeft u dit item reeds aangevraagd. Selecteer a.u.b. Ok als u toch wilt doorgaan met deze aanvraag.

Gekoppelde data


<http://www.worldcat.org/oclc/835500084>
library:oclcnum"835500084"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/835500084>
rdf:typeschema:Book
schema:about
<http://id.loc.gov/authorities/subjects/sh2007003908>
rdf:typeschema:Intangible
schema:name"Research and development projects--Costs--Econometric models."
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2013"
schema:description"We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1218425129>
schema:inLanguage"en"
schema:name"Price indexes for clinical trial research a feasibility study"
schema:publisher
schema:url
schema:url<http://www.nber.org/papers/w18918>

Content-negotiable representations

Venster sluiten

Meld u aan bij WorldCat 

Heeft u geen account? U kunt eenvoudig een nieuwe gratis account aanmaken.